Acorda stock: buy or sell?
September 20th, 2019
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States.
Should I buy Acorda stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Acorda stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Acorda Therapeutics stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 12 ratings published for ACOR stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-5-7||JPMorgan Chase & Co.||n/a||Hold|
|2019-1-2||JPMorgan Chase & Co.||n/a||Hold|
Acorda stock analysis
Acorda Therapeutics closed today at $3.49 and jumped a very good 2.95%.
Acorda Therapeutics shares jumped 2.95% to $3.49 today. ACOR is retaking the upward trend marking a new rising bottom heading to break out over $4.46.
After boosting an exceptional 27.46% in a week last week, Acorda Therapeutics closed this week at $3.49 and plummed a hair-raising -9.59%.
Since price and 10-weeks moving average lines crossed down early February, ACOR fell $-13.09 per share (-78.95%).
Acorda stock price history
Acorda stock went public on February 10th, 2006 with a price of $6.171. Since then, ACOR stock declined a -43.40%, with a yearly average of -3.30%.
1: Adjusted price after possible price splits or reverse-splits.
Acorda stock historical price chart
ACOR stock reached 52-week highs on November at $21.63, and all-time highs 2015-01-13 with a price of 45.45.
Acorda stock price target is $17.50Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' ACOR stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 11 price targets for Acorda Therapeutics stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-2||Stifel Nicolaus||Lowers Target||$12.00||$7.00||-41.7%|
|2019-8-2||Cantor Fitzgerald||Lowers Target||$20.00||$12.00||-40%|
|2019-5-7||JPMorgan Chase & Co.||Reiterates||n/a||$18.00||-|
|2019-1-23||HC Wainwright||Set Price Target||n/a||$33.00||-|
|2019-1-2||Oppenheimer||Set Price Target||n/a||$18.00||-|
|2019-1-2||Cantor Fitzgerald||Set Price Target||n/a||$32.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareSince February, when Acorda Therapeutics posted its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a scary loss of -19.86% to $471.43 million dollars. Nonetheless, its profit margin (compared to revenues) climbed to 7.14%, that is $33.68 million.
|2013||$336 M||-||$16 M4.9%||-|
|2014||$401 M||19.34%||$18 M4.4%||7.49%|
|2015||$493 M||22.71%||$11 M2.2%||-37.43%|
|2016||$520 M||5.47%||$-34.62 M-6.7%||-413.06%|
|2017||$588 M||13.22%||$-223.36 M-38.0%||545.21%|
|2018||$471 M||-19.86%||$34 M7.1%||-115.08%|
Quarterly financial resultsAcorda Therapeutics posted $69.15 M in sales for 2018-Q4, a -51.58% decline compared to previous quarter. Reported quarter earnings marked $9.60 million with a profit margin of 13.88%. Profit margin rocketed a 23.62% compared to previous quarter when profit margin was -9.74%. When comparing revenues to same quarter last year, Acorda sales marked a bloodcurdling slide and plunged a -63.29%. Looking back to recent quarterly results, Acorda posted 2 negative quarters in a row.
|2017-Q1||$119 M||-||$-19 M-15.8%||-|
|2017-Q2||$139 M||16.79%||$-8 M-5.9%||-56.61%|
|2017-Q3||$141 M||1.17%||$-25 M-17.9%||207.26%|
|2017-Q4||$188 M||33.55%||$-171 M-90.8%||578.96%|
|2018-Q1||$106 M||-43.65%||$-8 M-7.7%||-95.21%|
|2018-Q2||$153 M||44.40%||$46 M30.1%||-663.45%|
|2018-Q3||$143 M||-6.84%||$-14 M-9.7%||-130.11%|
|2018-Q4||$69 M||-51.58%||$10 M13.9%||-168.97%|
Acorda ownershipWhen you are planning to invest in a stock, it's worth to check its ownership structure.
Acorda shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 1.85% of all shares.
Bearish positions for ACOR stock account 0.00%, no big difference from last month.
For a better context understanding, the next table shows ownership data compared to other related companies:
|Market cap||$167.9 M||$13.5 B||$1.3 B||$10.8 B||$4.2 B|
|Total shares||48.1 M||179.5 M||98.7 M||515.9 M||51.5 M|
|Float shares||39.5 M||178.3 M||93.7 M||512.7 M||47.0 M|
|- Institutional holdings (%)||112.3%||102.9%||98.0%||86.2%||91.6%|
|- Insider holdings (%)||1.8%||0.4%||2.1%||1.1%||10.2%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$3.35 - $3.58|
|Average true range||$0.39|
|50d mov avg||$4.26|
|100d mov avg||$6.64|
|200d mov avg||$10.60|
Acorda performanceTo better understand Acorda Therapeutics performance you must compare its gains with other related stocks in same sector or industry. In the following table, we compare Acorda Therapeutics to BioMarin Pharmaceutical, Momenta Pharmaceuticals, Mylan and Repligen: